Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Poxel
  6. Summary
    POXEL   FR0012432516

POXEL

(POXEL)
  Report
Real-time Quote. Real-time Euronext Paris - 01/21 06:28:56 am
4.366 EUR   -2.72%
01/19POXEL : Corporate Presentation
PU
01/05POXEL : Corporate Profile January 2022
PU
01/04POXEL : Provisional calendar
CO
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
4.62(c) 4.66(c) 4.38(c) 4.488(c) 4.366 Last
36 580 22 433 94 401 29 584 10 892 Volume
-1.70% +0.87% -6.01% +2.47% -2.72% Change
More quotes
Estimated financial data (e)
Sales 2021 15,5 M 17,6 M 17,6 M
Net income 2021 -32,6 M -37,0 M -37,0 M
Net cash position 2021 36,4 M 41,3 M 41,3 M
P/E ratio 2021 -3,79x
Yield 2021 -
Sales 2022 16,8 M 19,1 M 19,1 M
Net income 2022 -35,4 M -40,2 M -40,2 M
Net Debt 2022 0,80 M 0,91 M 0,91 M
P/E ratio 2022 -3,51x
Yield 2022 -
Capitalization 129 M 146 M 146 M
EV / Sales 2021 5,95x
EV / Sales 2022 7,70x
Nbr of Employees 52
Free-Float 84,8%
More Financials
Company
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases. TWYMEEG« (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan since September 2021 for the treatment of type 2 diabetes. For the treatment of NASH,... 
More about the company
Ratings of Poxel
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about POXEL
01/19POXEL : Corporate Presentation
PU
01/05POXEL : Corporate Profile January 2022
PU
01/04POXEL : Provisional calendar
CO
01/03POXEL : Corporate Presentation
PU
2021POXEL : Corporate Presentation
PU
2021Poxel S.A. Appoints Jaspreet Singh to Scientific Advisory Board
CI
2021Corporate Profile November 2021
PU
2021Poxel Corporate Presentation
PU
2021POXEL : Corporate Profile October 2021
PU
2021POXEL : Corporate Presentation
PU
2021POXEL : 3rd quarter earnings
CO
2021POXEL : Corporate Profile September 2021
PU
2021Poxel S.A. Announces Executive Changes
CI
2021POXEL : Corporate Presentation
PU
2021POXEL : 2021 Half Year Financial Report
PU
More news
News in other languages on POXEL
2021POXEL : Andera Partners sous les 5% de capital et des votes
2021POXEL : Décembre 2021 Lettre Aux Actionnaires
2021POXEL : création d'un Conseil Scientifique
2021Ça s'en va et ça revient
2021EN DIRECT DES MARCHES : Saint-Gobain, Vivendi, EssilorLuxottica, Technip Energies, Carmat,..
More news
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,49 €
Average target price 15,95 €
Spread / Average Target 255%
EPS Revisions
Managers and Directors
Thomas Kuhn Chief Executive Officer & Director
Anne Renevot Chief Financial Officer & Executive Vice President
Pierre Legault Chairman
Takashi Kaneko Senior Vice President-Medical
David E. Moller Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
POXEL-8.71%146
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805